ERLOTINIB for Lung adenocarcinoma stage iv: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 203 adverse event reports in the FDA FAERS database where ERLOTINIB was used for Lung adenocarcinoma stage iv.
Most Reported Side Effects for ERLOTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 5,000 | 22.3% | 4,996 | 386 |
| Rash | 4,648 | 20.7% | 580 | 485 |
| Diarrhoea | 3,448 | 15.3% | 462 | 598 |
| Fatigue | 1,548 | 6.9% | 392 | 246 |
| Nausea | 1,366 | 6.1% | 284 | 290 |
| Drug ineffective | 1,207 | 5.4% | 159 | 101 |
| Off label use | 1,190 | 5.3% | 809 | 198 |
| Decreased appetite | 998 | 4.4% | 249 | 234 |
| Malignant neoplasm progression | 954 | 4.3% | 494 | 230 |
| Dry skin | 953 | 4.2% | 57 | 83 |
| Disease progression | 910 | 4.1% | 246 | 93 |
| Pruritus | 830 | 3.7% | 68 | 82 |
| Vomiting | 820 | 3.7% | 199 | 271 |
| Asthenia | 757 | 3.4% | 281 | 230 |
| Dyspnoea | 738 | 3.3% | 265 | 283 |
Other Indications for ERLOTINIB
Lung neoplasm malignant (9,207)
Non-small cell lung cancer (3,359)
Product used for unknown indication (3,040)
Pancreatic carcinoma (1,089)
Malignant respiratory tract neoplasm (876)
Lung adenocarcinoma (841)
Neoplasm malignant (565)
Bronchial carcinoma (397)
Non-small cell lung cancer metastatic (290)
Bone cancer (174)
Other Drugs Used for Lung adenocarcinoma stage iv
PEMBROLIZUMAB (1,644)
PEMETREXED (1,510)
CARBOPLATIN (1,138)
CISPLATIN (303)
OSIMERTINIB (278)
PACLITAXEL (223)
BEVACIZUMAB (213)
DOCETAXEL (188)
CRIZOTINIB (164)
NIVOLUMAB (163)